Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)

NCT04835584 is registered in ClinicalTrials.gov with Kartos Therapeutics, Inc. as lead sponsor.

NCT NCT04835584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04835584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With a Tyrosine Kinase Inhibitor (TKI) in Patients With Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)
Lead sponsor
Kartos Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 7, 2021
Completion date
June 30, 2026
Enrollment
109 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia